Please assess the completion status of the following clinical trial:

Trial Title: Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-valvular Atrial Fibrillation~* CHA2DS2-VASc Score \> or = to 2~* Never been treated with Apixaban (Eliquis) or prior treatment of \< 1 month~* Candidate for oral anticoagulation as assessed by a treating physician~Exclusion Criteria:~* Valvular Atrial Fibrillation (Rheumatic valve disease,Moderate or greater mitral stenosis,Mechanical cardiac valve)~* Active Bleeding~* Prior treatment with Apixaban \>1 month~* Recent stroke within 7 days~* Dementia~* Implanted devices not compatible with MRI/any cardiac implanted device~* Claustrophobia~* Active alcohol/drug abuse~* Life expectancy \< 1 year~* Taking asprin with \>100mg doses~* Known hypersensitivity to warfarin or Apixaban~* Severe renal insufficiency~* Prior severe bleeding (Intracranial bleeding (subdural, subarachnoid, intraparenchymal bleeding),GI bleed requiring transfusion,Bleeding from other sites requiring transfusion)~* Psychosocial reasons that make study participation impractical~* Currently enrolled in another IND or IDE trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints~* Co-morbid condition(s) that could limit the subject's ability to participate in the trial or to comply with follow-up requirements, or that could impact the scientific integrity of the study.~* Prisoners or subjects who are involuntarily incarcerated~* Subjects who are compulsorily detained for treatment of either psychiatric or physical illness~* Current or expected systemic treatment with strong dual inhibitors of CYP3A4 and P-gp (Any one of rifampin, carbamazepine, phenytoin, St. John's Wort, ketoconazole, itraconazole, ritonavir, clarithromycin)~* Need for dual anti-platelet therapy with aspirin and another agent such as thienopyridine

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eliquis (Type: ACTIVE_COMPARATOR): None
- Warfarin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).